AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology medicines, Rinvoq and Skyrizi, which not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.

China Universal Asset Management Co. Ltd. reduced its stake in shares of AbbVie Inc. (NYSE: ABBV) by 32.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,906 shares of the company's stock after selling 5,131 shares during the quarter. China

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease management NORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL).

AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.

NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

AbbVie is a Dividend King that's a successful player in multiple critical therapeutic areas. Enbridge is an energy infrastructure leader with an especially attractive dividend.

Cash Flowing Companies that Raise Dividends

AbbVie, RTX and IBM headline Zacks??? top analyst picks after strong earnings beats and solid backlog, cloud and AI-driven momentum.

ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.

Executives from AbbVie (NYSE: ABBV) outlined upcoming clinical milestones and development priorities across hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), and several earlier-stage immunology programs during a recent discussion focused on differentiation, combination strategies, and next-generation platforms. HS: IL-1 bispecific lutikizumab and RINVOQ readouts expected by year-end Company leaders emphasized that HS remains a significant unmet-need